Affiliate disclosure
GLP Agonists is an editorial publication that earns revenue through affiliate partnerships with some — but not all — of the providers reviewed on this site. When a reader clicks a partner link and signs up for a service, we may earn a commission. This commission is paid by the provider, not the reader; it does not change the price of the service.
How partnerships interact with rankings
Partnership status is not an input to the scoring rubric described in our methodology. A provider's score and category awards are determined by the same fourteen criteria applied to every provider in the review. Partners do not receive better scores in exchange for partnership status, and non-partners are not penalized.
Where a partner ranks ahead of a competitor in our review — including in our Editor's Pick, Best Overall, and category awards — that ranking reflects the rubric output, not the commercial relationship. We will publicly publish a category change if rescoring moves a non-partner ahead of a partner.
How outbound links are marked
Affiliate links on this site are marked with the rel="sponsored" attribute, in compliance with Google Webmaster Guidelines and FTC disclosure expectations. These links open in a new browser tab. The disclosure bar at the top of every page on this site is visible above the fold and is not dismissible.
Medical disclaimer
GLP Agonists is an editorial publication, not a medical provider. We do not establish a clinician-patient relationship with any reader. Content on this site is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified, licensed healthcare provider before starting, stopping, or changing any medication, including any GLP-1 receptor agonist.
Pricing, dose, eligibility, prescription decisions, and clinical outcomes are determined by the prescribing provider you sign up with — not by GLP Agonists. Providers reviewed on this site are responsible for their own clinical decisions, intake processes, and dispensing practices. We do not control, and cannot warrant, any aspect of any provider's clinical service.
Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved drugs. They are prepared by licensed compounding pharmacies under prescriber direction. Following the FDA's resolution of declared shortages of brand-name GLP-1 medications in 2025, the agency's enforcement discretion regarding compounded versions ended (April 22, 2025 for 503A pharmacies; May 22, 2025 for 503B outsourcing facilities). Compounded GLP-1s may be prescribed only where a licensed healthcare provider documents medical necessity. If you are unsure whether a compounded pathway is appropriate for you, ask the prescribing clinician directly.
If you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), GLP-1 receptor agonists are contraindicated. If you are pregnant, planning to become pregnant, or breastfeeding, GLP-1s are generally not appropriate. If you are taking insulin or sulfonylureas, GLP-1s carry interaction risk. None of this is comprehensive medical advice — it is a partial illustration of why a clinician evaluation is essential before starting any GLP-1 therapy.
Data accuracy
All pricing and program details on this site are sourced from primary public materials — most often the provider's own website — and reviewed quarterly. Pricing is dynamic in this category, and providers may change rates, plan structures, or dose-pricing schedules without notice. We make every reasonable effort to keep the comparison data current, but we cannot guarantee real-time accuracy. Always confirm current pricing on the provider's site before committing to a plan.
The "Prices last updated" date on the comparison page reflects the date of the most recent comprehensive review of all entries. Individual rows may have been verified more recently in response to provider notification or reader correction.
Corrections policy
If you believe any claim on this site is inaccurate — whether you're a provider, a patient, a clinician, or a regulator — please contact us at glpagonists@gmail.com with documentation of the issue. We will:
- Acknowledge receipt within five business days.
- Verify the documented claim against our sources.
- Update the page within ten business days of verification, with a dated correction note inline on the affected page.
- If a score or ranking changes as a result of the correction, recompute the affected category and update the homepage and comparison table accordingly.
We do not silently rewrite published content. Corrections are noted on the affected page; significant corrections also receive a note in the next publication cycle.
Contact
For all inquiries — editorial corrections, partnership questions, press, reader feedback — please write to glpagonists@gmail.com.
Last updated: May 4, 2026. Disclosure version 1.0.